ION expands ETF trading capabilities with Tradeweb integration
WALTHAM, Mass. - Ardelyx, Inc. (NASDAQ:ARDX) presented new data on its phosphate absorption inhibitor XPHOZAH at the American Society of Nephrology's Kidney Week in Houston, according to a company statement on Friday. The biopharmaceutical company, currently valued at $1.35 billion, has seen impressive revenue growth of 58.12% over the last twelve months despite not yet achieving profitability, according to InvestingPro data.
The biopharmaceutical company shared results from the first real-world study of XPHOZAH, which showed patients prescribed the medication experienced an average reduction in serum phosphate levels of nearly 1 mg/dL. Nearly half of participants (45.3%) achieved a reduction of 1 mg/dL or more, while 25.1% saw reductions of 2 mg/dL or greater.
XPHOZAH is FDA-approved to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy when patients have inadequate response to phosphate binders or cannot tolerate them. The drug works by blocking phosphate absorption at the primary pathway and is administered as a single tablet twice daily. Analysts appear optimistic about the drug's potential, with InvestingPro data showing a strong buy consensus and price targets suggesting up to 95% upside potential from current levels. The company's stock has already gained over 52% in the past six months.
A separate patient survey revealed that 63% of respondents reported improved phosphate levels since starting XPHOZAH. Among those reporting changes, 69% indicated a better outlook on serum phosphate control, with 44% attributing this to better phosphate control, 39% to improved bowel movements, and 14% to lower pill burden.
The company also presented a post-hoc analysis of its Phase 3 BLOCK study, which showed XPHOZAH improved bowel movements in patients with end-stage kidney disease who experienced constipation at baseline. Constipation affects 30-40% of patients with end-stage kidney disease receiving dialysis.
Additionally, a cost-effectiveness analysis conducted by Kyowa Kirin Co., Ltd., Ardelyx's collaboration partner in Japan, concluded that tenapanor (the active ingredient in XPHOZAH) was cost-effective for hemodialysis patients from the Japanese public healthcare payer's perspective.
Diarrhea was reported as the most common side effect in clinical trials, occurring in 43-53% of patients taking XPHOZAH.
In other recent news, Ardelyx Inc. reported its financial results for the third quarter of 2025, revealing a revenue of $110.3 million. This figure exceeded analysts' expectations, which had forecasted revenue of $100.48 million. The company maintained its earnings per share (EPS) forecast at -$0.06, aligning with previous estimates. These financial results indicate a stronger performance than anticipated. Additionally, the company's stock experienced a modest increase in aftermarket trading following the announcement. While the revenue beat forecasts, the earnings per share remained consistent with prior projections. These developments highlight Ardelyx's current financial standing and investor interest.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.